Last Price$61.4(0.0%)
Market Cap$7,773.1M
LTM Interest Expense
$18.1M
YoY Growth
-3.6%
3Y CAGR
+34.0%
5Y CAGR
+9.2%
Stock quality & Intrinsic value
8/10
10.3% overvalued
Halozyme Therapeutics, Inc. Interest Expense
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Expense | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $3,274.1K | $5,581.0K | $5,201.0K | $20.0M | $22.0M | $18.0M | $11.6M | $20.4M | $7,526.0K | $16.9M | $18.8M | $18.1M |
Overvalued or undervalued?
Check the intrinsic value for HALO
and see if it's the right time to invest.
Halozyme Therapeutics, Inc. (HALO) Interest Expense comparison analysis
General
LTM Interest Expense
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Halozyme Therapeutics, Inc.HALO
$18.1M
(3.6%)
34.0%
9.2%
Median Peer Set
$26.1M
(28.2%)
(0.1%)
(2.0%)
Royalty Pharma plcRPRX
$225.8M
20.8%
10.8%
(3.4%)
Alnylam Pharmaceuticals, Inc.ALNY
$141.9M
17.0%
(0.3%)
33.5%
Regeneron Pharmaceuticals, Inc.REGN
$55.2M
(24.4%)
(1.2%)
12.8%
United Therapeutics CorporationUTHR
$42.9M
(27.7%)
32.1%
(0.6%)
Vertex Pharmaceuticals IncorporatedVRTX
$30.6M
(30.6%)
(20.8%)
(12.2%)
BioNTech SEBNTX
$21.6M
(83.8%)
54.7%
40.6%
BioMarin Pharmaceutical Inc.BMRN
$12.3M
(28.8%)
(7.0%)
(12.1%)
Summit Therapeutics Inc.SMMT
$8,687.0K
(47.2%)
53.2%
178.3%
argenx SEARGX
$2,040.4K
26.3%
(48.5%)
(16.0%)
BeiGene, Ltd.BGNE
$0.0
(100.0%)
N/A
(100.0%)
HALO key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.1 0.0% | 1.0 671.8% | 3.8 287.0% | 8.8 130.7% | 13.7 56.0% | 13.6 (0.3%) | 56.1 311.7% | 42.3 (24.5%) | 54.8 29.5% | 75.3 37.5% | 135.1 79.3% | 146.7 8.6% | 316.6 115.8% | 151.9 (52.0%) | 196.0 29.1% | 267.6 36.5% | 443.3 65.7% | 660.1 48.9% | 829.3 25.6% | 1,015.3 22.4% |
| Cost of Goods Sold (COGS) | 0.1 | 0.4 | 0.2 | 0.3 | 0.3 | 1.0 | 0.3 | 1.1 | 6.2 | 22.7 | 29.2 | 33.2 | 31.2 | 10.1 | 45.5 | 43.4 | 81.4 | 139.3 | 192.4 | 159.4 |
% margin | 0.1 59.1% | 0.5 55.5% | 3.6 93.7% | 8.4 96.2% | 13.4 97.7% | 12.6 92.8% | 55.8 99.5% | 41.2 97.4% | 48.6 88.6% | 52.6 69.8% | 105.8 78.3% | 113.5 77.4% | 285.5 90.2% | 141.7 93.3% | 150.4 76.8% | 224.2 83.8% | 361.9 81.6% | 520.8 78.9% | 636.9 76.8% | 855.9 84.3% |
| Operating Expenses | 13.6 | 16.1 | 31.7 | 58.9 | 71.8 | 66.9 | 75.7 | 94.9 | 129.0 | 115.6 | 133.3 | 196.7 | 204.5 | 211.1 | 218.1 | 80.0 | 86.0 | 253.3 | 299.3 | 304.4 |
| Research & Development Expenses (R&D) | 10.2 | 9.2 | 20.6 | 44.2 | 56.6 | 51.8 | 57.6 | 70.0 | 96.6 | 79.7 | 93.2 | 150.8 | 150.6 | 150.3 | 140.8 | 34.2 | 35.7 | 66.6 | 76.4 | 79.0 |
| Selling, General & Administrative Expenses (SG&A) | 3.4 | 6.9 | 11.2 | 14.6 | 15.2 | 15.1 | 18.1 | 24.8 | 32.3 | 35.9 | 40.0 | 45.9 | 53.8 | 60.8 | 77.3 | 45.7 | 50.3 | 143.5 | 149.2 | 154.3 |
% margin | (13.6) (10,660.7%) | (15.6) (1,587.3%) | (28.2) (740.9%) | (50.4) (575.5%) | (58.5) (427.6%) | (54.3) (398.2%) | (19.8) (35.4%) | (53.6) (126.7%) | (80.4) (146.8%) | (63.0) (83.7%) | (27.5) (20.3%) | (83.2) (56.7%) | 81.0 25.6% | (69.3) (45.7%) | (67.6) (34.5%) | 144.3 53.9% | 275.9 62.2% | 267.5 40.5% | 337.6 40.7% | 551.5 54.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 1.7 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 15.0 | 6.4 | 15.9 | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.3 | 5.6 | 5.2 | 20.0 | 22.0 | 18.0 | 11.6 | 20.4 | 7.5 | 16.9 | 18.8 | 18.1 |
| Pre-tax Income | (13.3) | 0.0 | 0.0 | (48.7) | (58.4) | (53.2) | (19,769.9) | (53.6) | (83.5) | (68.4) | (32.2) | (101.9) | 61.6 | (79.8) | (72.3) | 129.3 | 248.5 | 248.9 | 348.3 | 557.1 |
% effective tax rate | (0.3) 2.2% | (0.8) 0.0% | (4.3) 0.0% | (0.1) 0.1% | 0.0 0.0% | (1.0) 1.9% | (1.2) 0.0% | (1.1) 2.1% | 2.0 (2.5%) | 3.8 (5.6%) | 3.5 (10.9%) | 1.2 (1.1%) | (1.4) (2.2%) | 0.5 (0.7%) | (0.0) 0.0% | 0.2 0.2% | (154.2) (62.0%) | 46.8 18.8% | 66.7 19.2% | 113.0 20.3% |
% margin | (13.3) (10,435.9%) | (14.8) (1,502.6%) | (23.9) (628.9%) | (48.7) (555.2%) | (58.4) (426.9%) | (53.2) (390.8%) | (19.8) (35.2%) | (53.6) (126.5%) | (83.5) (152.3%) | (68.4) (90.8%) | (32.2) (23.9%) | (103.0) (70.2%) | 63.0 19.9% | (80.3) (52.9%) | (72.2) (36.9%) | 129.1 48.2% | 402.7 90.8% | 202.1 30.6% | 281.6 34.0% | 444.1 43.7% |
| EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.46 | (0.56) | (0.50) | 0.95 | 2.86 | 1.48 | 2.13 | 3.50 |
| Diluted EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.45 | (0.56) | (0.50) | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 |
% margin | (13.4) (10,498.5%) | (14.5) (1,477.8%) | (28.2) (740.9%) | (49.4) (563.5%) | (56.9) (416.3%) | (52.7) (387.2%) | (18.7) (33.3%) | (52.5) (124.0%) | (79.0) (144.1%) | (61.0) (81.0%) | (25.4) (18.8%) | (79.5) (54.2%) | 83.2 26.3% | (69.3) (45.7%) | (56.6) (28.9%) | 153.0 57.2% | 259.0 58.4% | 315.5 47.8% | 451.9 54.5% | 656.5 64.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Halozyme Therapeutics, Inc.'s Interest Expense?
As of today, Halozyme Therapeutics, Inc.'s last 12-month Interest Expense is $18.1M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Halozyme Therapeutics, Inc.'s Interest Expense growth rate?
Over the last year, Halozyme Therapeutics, Inc.'s Interest Expense growth was (3.6%). The average annual Interest Expense growth rates for Halozyme Therapeutics, Inc. have been 9.6% over the past three years, 9.2% over the past five years.
3) Is Halozyme Therapeutics, Inc.'s Interest Expense growth rate Good?
Over the last year, Halozyme Therapeutics, Inc.'s Interest Expense growth was (3.6%), which is lower than industry growth of (0.7%). It indicates that Halozyme Therapeutics, Inc.'s Interest Expense growth is Good.